1-16 of 16
Margaret von Mehren
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma

Scott M. Schuetze, Karla V. Ballman, Rachel Heise, Kristen N. Ganjoo, Elizabeth J. Davis, Suzanne George, Melissa A. Burgess, Edwin Choy, Dale R. Shepard, Gabriel Tinoco, Angela Hirbe, Ciara M. Kelly, Steven Attia, Hari A. Deshpande, Gary K. Schwartz, Brittany L. Siontis, Richard F. Riedel, Margaret von Mehren, Erin Kozlowski, Helen X. Chen, Caroline Astbury, Brian P. Rubin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4584–4592.
https://doi.org/10.1158/1078-0432.CCR-23-3817
Published: 15 October 2024
View article titled, A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
Open the PDF for A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma in another window
Includes: Supplementary data
Journal Articles

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Sujana Movva, Sahar Matloob, Elizabeth A. Handorf, Edwin Choy, Priscilla Merriam, Douglas B. Flieder, Kathy Q. Cai, Yan Zhou, Eric D. Tetzlaff, Cheyenne Pagan, Emma Barker, Rosanna Veggeberg, Delia Zumpano, Lori Rink, Margaret von Mehren, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 315–322.
https://doi.org/10.1158/1078-0432.CCR-23-2469
Published: 17 January 2024
View article titled, SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Open the PDF for SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1268–1276.
https://doi.org/10.1158/1078-0432.CCR-21-2037
Published: 01 April 2022
View article titled, Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Open the PDF for Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers in another window
Includes: Supplementary data
Journal Articles

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Sebastian Bauer, Michael C. Heinrich, Suzanne George, John R. Zalcberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren, Patrick Schöffski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6333–6342.
https://doi.org/10.1158/1078-0432.CCR-21-1864
Published: 01 December 2021
View article titled, Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <em>KIT/PDGFRA</em> Mutations in the Phase III INVICTUS Study
Open the PDF for Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <em>KIT/PDGFRA</em> Mutations in the Phase III INVICTUS Study in another window
Includes: Supplementary data
Journal Articles

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Margaret von Mehren, Suzanne George, Michael C. Heinrich, Scott M. Schuetze, Jeffrey T. Yap, Jain Q. Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin Belinsky, Katherine A. Janeway, Jason L. Hornick, Douglas B. Flieder, Rashmi Chugh, Lori Rink, Annick D. Van den Abbeele
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1837–1845.
https://doi.org/10.1158/1078-0432.CCR-19-1069
Published: 15 April 2020
View article titled, Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
Open the PDF for Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study in another window
Journal Articles

Abstract A02: Succinate dehydrogenase deficiency in a PDGFRA mutated gastrointestinal stromal tumor

Martin G. Belinsky, Lori Rink, Kathy K. Cai, Biao Luo, Yan Zhou, Margaret von Mehren
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2_Supplement): A02.
https://doi.org/10.1158/1557-3265.SARCOMAS17-A02
Published: 15 January 2018
View article titled, Abstract A02: Succinate dehydrogenase deficiency in a PDGFRA mutated gastrointestinal stromal tumor
Journal Articles

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

Phillip Zook, Harsh B. Pathak, Martin G. Belinsky, Lawrence Gersz, Karthik Devarajan, Yan Zhou, Andrew K. Godwin, Margaret von Mehren, Lori Rink
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1): 171–180.
https://doi.org/10.1158/1078-0432.CCR-16-0529
Published: 02 January 2017
View article titled, Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
Open the PDF for Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Karthik Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. Burris, III, Jeffrey R. Infante
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4775–4784.
https://doi.org/10.1158/1078-0432.CCR-12-0589
Published: 30 August 2012
View article titled, Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
Open the PDF for Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

Roger B. Cohen, Suzanne F. Jones, Charu Aggarwal, Margaret von Mehren, Jonathan Cheng, David R. Spigel, F. Anthony Greco, Mariangela Mariani, Maurizio Rocchetti, Roberta Ceruti, Silvia Comis, Bernard Laffranchi, Jurgen Moll, Howard A. Burris
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6694–6701.
https://doi.org/10.1158/1078-0432.CCR-09-1445
Published: 02 November 2009
View article titled, A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

George D. Demetri, Paolo G. Casali, Jean-Yves Blay, Margaret von Mehren, Jeffrey A. Morgan, Rossella Bertulli, Isabelle Ray-Coquard, Philippe Cassier, Monica Davey, Hossein Borghaei, Daniel Pink, Maria Debiec-Rychter, Wing Cheung, Stuart M. Bailey, Maria Luisa Veronese, Annette Reichardt, Elena Fumagalli, Peter Reichardt
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5910–5916.
https://doi.org/10.1158/1078-0432.CCR-09-0542
Published: 14 September 2009
View article titled, A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
Open the PDF for A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors in another window
Journal Articles

Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma

Jean-Yves Blay, Margaret von Mehren, Brian L. Samuels, Michael P. Fanucchi, Isabelle Ray-Coquard, Brigid Buckley, Leen Gilles, Claudia Lebedinsky, Yusri A. Elsayed, Axel Le Cesne
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6656–6662.
https://doi.org/10.1158/1078-0432.CCR-08-0336
Published: 16 October 2008
View article titled, Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Open the PDF for Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma in another window
Journal Articles

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

Howard L. Kaufman, Heinz-Josef Lenz, John Marshall, Deepti Singh, Chris Garett, Christine Cripps, Malcolm Moore, Margaret von Mehren, Richard Dalfen, William J. Heim, Robert M. Conry, Walter J. Urba, Al B. Benson, III, Maria Yu, Judy Caterini, Seunghee Kim-Schulze, Mark DeBenedette, Danielle Salha, Thorsten Vogel, Ileana Elias, Neil L. Berinstein
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4843–4849.
https://doi.org/10.1158/1078-0432.CCR-08-0276
Published: 01 August 2008
View article titled, Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Open the PDF for Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer in another window
Journal Articles

Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas

Jay E. Johnson, Robert J. Varkonyi, Jaclyn Schwalm, Ryan Cragle, Andres Klein-Szanto, Arthur Patchefsky, Edna Cukierman, Margaret von Mehren, Dominique Broccoli
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5347–5355.
https://doi.org/10.1158/1078-0432.CCR-05-0684
Published: 01 August 2005
View article titled, Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas
Open the PDF for Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas in another window
Journal Articles

Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling

Chi Tarn, Erin Merkel, Adrian A. Canutescu, Wei Shen, Yuliya Skorobogatko, Martin J. Heslin, Burton Eisenberg, Ruth Birbe, Arthur Patchefsky, Roland Dunbrack, J. Pablo Arnoletti, Margaret von Mehren, Andrew K. Godwin
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (10): 3668–3677.
https://doi.org/10.1158/1078-0432.CCR-04-2515
Published: 16 May 2005
View article titled, Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling
Open the PDF for Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling in another window
Journal Articles

The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma

Margaret von Mehren, Philip Arlen, James Gulley, André Rogatko, Harry S. Cooper, Neal J. Meropol, R. Katharine Alpaugh, Monica Davey, Susan McLaughlin, Mary T. Beard, Kwong Y. Tsang, Jeffrey Schlom, Louis M. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (5): 1181–1191.
Published: 01 May 2001
View article titled, The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma
Open the PDF for The Influence of Granulocyte Macrophage Colony-Stimulating Factor and Prior Chemotherapy on the Immunological Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma in another window
Journal Articles

Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas

Margaret von Mehren, Philip Arlen, Kwong Y. Tsang, André Rogatko, Neal Meropol, Harry S. Cooper, Monica Davey, Susan McLaughlin, Jeffrey Schlom, Louis M. Weiner
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2219–2228.
Published: 01 June 2000
View article titled, Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas
Open the PDF for Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas in another window